Mechanical Circulatory Support Therapy
Save. Support. Restore.
Mechanical circulatory support (MCS) therapy boosts hemodynamic function in failing hearts via ventricular assist devices (VADs). For cardiac transplant-eligible patients facing an extended wait for a donor heart, MCS can provide Bridge-to-Transplantation Therapy, both for intermediate support and for optimization of long-term transplant outcomes.3 Patients who are ineligible for transplant may benefit from MCS as Destination Therapy, which provides chronic support.4 For other patients unable to wean from cardiopulmonary bypass, MCS can provide support during the Post-Cardiotomy Recovery period.5 Some VADs are specially designed to provide short-term support in acute hemodynamic compromise while more definitive treatment decisions are made.5
MCS can trigger a favorable physiological cascade of events, significantly improving both survival and quality of life. Cardiac output is restored at once, enhancing the functioning of end organs such as the liver and kidneys. Molecular and cellular improvements in the myocardium follow, as well as improvement in neurohormonal modulation. With timely intervention, most NYHA Class IV patients treated with a VAD improve to NYHA Class I or II.27 Indeed, there are even patients for whom VAD therapy serves as a bridge to full recovery, allowing device removal.9
Documented Benefits of MCS
- Restore cardiac output and bloodflow
- Help patients resume their daily lives with a significant reduction of heart failure symptoms
- Improve end-organ function
- Initiate molecular and cellular improvements in the myocardium
- Facilitate a consistent improvement in NYHA functional class from Class IV to Class I or II for most patients
"Survival with an implanted left ventricular assist device, particularly a HeartMate II® type device, is substantially better than medical therapy. We’ve known this for a long time."
David Dyke, MD
Cardiologist University of Michigan
"Patients with advanced heart failure have a progressively debilitating illness that not only dramatically decreases their life expectancy but also significantly affects the quality of their life and one thing we’ve seen with VAD therapy is that in appropriately selected patients..."
Jonathan Haft, MD
Cardiac Surgeon University of Michigan
Introducing a new website to help clinicians understand the life-changing potential of HeartMate II. You'll find helpful information to familiarize yourself with the HeartMate II clinical experience and benefits, and assistance to identify appropriate patients for timely referral. Learn More